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Passive Antibody Therapy: Potentially the First
COVID-19 Treatment
Caterina Erdas

While the world anxiously waits for a
COVID-19 vaccine, thousands of people are in critical
condition, in need of help today. Scientists are wondering what tools they have now to prevent the spread of
COVID-19 and help save the lives of patients in critical
condition. Passive antibody therapy may be the solution.
An antibody is a small molecule created by the
immune system to help fight an infection. Humans
only obtain an effective antibody for an infection after
they have become infected. Once the body is initially
infected, a chain of immune system processes is set off,
including the development of a specialized antibody.
Through the process of trial and error, the body develops an antibody, creates millions of copies, and disperses them throughout the body in the blood stream.
An antibody has a specialized region that binds to the
protein coating of a virus or the outer membrane of an
invasive cell.1
There are many types of antibodies that work
in different ways to neutralize an infection. Some work
by completely surrounding the infectious agent and
preventing it from replicating. Other antibodies bind
to the infectious agent and tag it for other cells in the
immune system to kill it.1 Once the infection is cleared,
the immune system will keep creating that antibody
for a short period of time, or for the rest of the human’s
life. No matter the strategy, antibodies are a powerful
and effective biological adaptation to fight an infection.
The idea behind passive antibody treatment
is: Why re-invent the wheel? Humans who have just recovered from an infection, in our case COVID-19, will
have high levels of the effective, specialized antibody
in their blood. Theoretically, if you take the convales-

cent plasma (filtered blood that doesn’t have any blood
cells but does have the antibodies for the pathogen of
interest) from the recovered patient and inject it into
a sick or susceptible patient, they will have the antibodies to fight off the infection. The immune system
created a great treatment, so instead of synthesizing
anew treatment, which takes a lot of time, doctors can
give a plasma transplant from a recovered patient to a
critical patient and potentially save their life.
Doctors and scientists have been trying passive antibody treatment for coronaviruses in general
and with COVID-19. In SARS1 and MERS, studies
showed that convalescent plasma administered early
on in the infection improved the health of patients.
In China, convalescent plasma was administrated to
10 COVID-19 patients, and all 10 patients showed
improvement after 1-3 days of treatment. There are
other similar studies that show promising results but
have small sample sizes and study design limitations.
While the extent of the effectiveness of passive antibody treatment cannot currently be determined, the
data available suggests that antibody treatment is not
harmful and could improve the symptoms of patients
permanently.2
The first step to start treating many COVID-19
patients with passive antibody testing is scientific validation. Safety is the first question that scientists need
to answer in a rigorous clinical study, followed by
evaluating passive antibody testing effectiveness in
mildly ill to critically ill adult patients, and finally
children. After the extent of the treatment is
characterized, a structural framework needs to be
built to collect and distribute convalescent plasma.
Recovered people from COVID-19 are not hard to
find, but blood donation
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centers are facing severe blood short- ages because
they have had to close their hospital locations.2
Scientific investigation and a solution
to collect large quantities of convalescent plasma is
needed before passive antibody testing can be widely
administered. In conclusion, passive antibody treatment has the potential to save the lives of patients and
prevent the spread of COVID-19 before a vaccine is
created and distributed. If you contract COVID-19 and
fully recover, look into convalescent plasma donation.
Your donation could be invaluable in saving a patient
with COVID-19 or fueling research for a long-term
COVID-19 passive antibody treatment.
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